Dainippon Sumitomo up 277yen also.
They only have the Japanese and Asian market.
Paid ICPT $15m in 2011 with milestone
payments of $300m.
NASH effects about 5% of the lean population,
20% of the obese and 50% of morbidly obese.
The US market is the gold market.
Maybe someone will step up.
It's been 2 years since the FDA approved IMC's
2b trial for NASH.
immuron 2b nash trial
There's ASH NASH c.difficile research and revenue from
Travelan.
Dainippon Sumitomo up 277yen also.They only have the Japanese...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
